title: [Effect of combined therapy using complex of natural cytokines and antimicrobial peptides in urogenital infections caused by Chlamydia and Mycoplasma].
abstract: OBJECTIVE
  To study efficacy of complex therapy of urogenital infections caused by Chlamydia and Mycoplasma using immunomodulator Superlimph.
  
  
  METHODS
  Fifty males and thirty six females ages 22 - 47 years old with chronic urogenital infections--cervicitis and vulvovaginitis (females), prostatitis (males)--were studied. PCR and bacteriologic methods were used for diagnostics of mixed infection and microbiota efficiency. Patients were divided on 3 groups according to treatment protocol. Twenty patients (group 1)--standard therapy (josamycin), 48 patients received immunomodulator (suppositorium) before treatment with josamycin (group 2), 18 patients were simultaneously treated with josamycin and immunomodulator (group 3).
  
  
  RESULTS
  Combinations of Chlamydia trachomatis, Ureaplasma urealyticum, Gardnerella vaginalis and Mycoplasma genitalium were identified in 30 - 35% of cases before treatment. After treatment with josamycin (group 1) or simultaneous therapy with josamycin and immunomodulator (group 3) considerable suppression of growth and elimination of both main pathogens and members of microbiota. Use of immunomodulator (group 2) in some cases resulted elimination of main pathogens and associated opportunistic microflora.
  
  
  CONCLUSIONS
  Microbiological monitoring in 97% cases demonstrated therapeutic effect of immunomodulator Superlymph on urogenital infections associated with Chlamydia and Mycoplasma and disbiotic microbiota of urogenital tract.
authors: I V
authors: IV
authors: Khamaganova
authors: Kh B
authors: KhB
authors: Akhmedov
authors: N P
authors: NP
authors: Tarabrina
authors: S S
authors: SS
authors: Khromova
authors: M V
authors: MV
authors: Mezentseva
authors: L V
authors: LV
authors: Koval'chuk
authors: L V
authors: LV
authors: Gankovskaia
authors: L A
authors: LA
authors: Degtiareva
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage*; D002689:Chlamydia; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D016207:Cytokines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015570:Josamycin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009174:Mycoplasma; D009175:Mycoplasma Infections / Q000188:drug therapy* / Q000382:microbiology; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D002575:Uterine Cervicitis / Q000188:drug therapy* / Q000382:microbiology; D014848:Vulvovaginitis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D016207:Cytokines; D015570:Josamycin